|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.004 AUD | 0.00% |
|
0.00% | +14.29% |
| Mar. 25 | Avecho Biotechnology Begins Patient Recruitment for Phase Three Anti-Insomnia Drug Trial | MT |
| Mar. 14 | Avecho to Push Forward with Phase III Trial of Anti-Insomnia Drug | MT |
Avecho Biotechnology Limited reported earnings results for the half year ended June 30, 2023. For the half year, the company reported sales was AUD 0.446439 million compared to AUD 0.758239 million a year ago. Net loss was AUD 2.13 million compared to AUD 0.777674 million a year ago.
Basic loss per share from continuing operations was AUD 0.0011 compared to AUD 0.0004 a year ago. Diluted loss per share from continuing operations was AUD 0.0011 compared to AUD 0.0004 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +14.29% | 8.27M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
AVECHO BIOTECHNOLOGY LIMITED 
